fropenem has been researched along with Helicobacter Infections in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Furukawa, K; Ito, J; Kawai, F; Matsuo, T; Mikami, Y; Mizuno, A; Mori, N; Ohkushi, D; Sakurai, A; Starkey, J; Uehara, Y; Yamasaki, M; Yoshino, K | 1 |
| Hirata, Y; Kawabe, T; Maeda, S; Mitsuno, Y; Ogura, K; Ohmae, T; Omata, M; Shibata, W; Yanai, A; Yoshida, H | 1 |
| Mitsuno, Y; Yoshida, H | 1 |
1 review(s) available for fropenem and Helicobacter Infections
| Article | Year |
|---|---|
Infected aortic aneurysm caused by Helicobacter cinaedi: case series and systematic review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Infected; Anti-Bacterial Agents; Aortic Aneurysm; beta-Lactams; Blood Culture; Female; Follow-Up Studies; Helicobacter; Helicobacter Infections; Humans; Immunocompromised Host; Japan; Male; Middle Aged; RNA, Ribosomal, 16S; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
2 trial(s) available for fropenem and Helicobacter Infections
| Article | Year |
|---|---|
Efficacy and safety of faropenem in eradication therapy of Helicobacter pylori.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged | 2007 |
[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactams; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2002 |